UltraOral Ltd. is an Israeli nutraceutical and drug delivery platform company developing patent-protected thermo-active functional chewing gum technology. Our gums self-warm to a controlled, fully FDA-compliant temperature range during chewing, creating a targeted thermal environment inside the mouth that significantly enhances the absorption of pharmaceutical and nutraceutical active ingredients through the intraoral tissue into the bloodstream.
 
The technology behind UltraOral is rooted in established scientific principles: higher temperature increases molecular kinetic energy, which increases the rate of drug/active compounds permeation across biological membranes in the mouth. By engineering a precise, reproducible warming response directly at the intraoral site of absorption, we bridge the gap between conventional oral delivery and the rapid onset typically associated with injectable routes — while completely bypassing GI tract and liver degradation and slow onset of action when swallowing pills/capsules/liquids.
 
Our technology platform is protected by a growing international patent portfolio spanning multiple countries, covering the thermo-active delivery mechanism, formulation architecture, and advanced encapsulation methods.
 
UltraOral operates a B2B licensing model. Rather than focusing on heavy manufacturing of consumer products, we license our platform technology to pharmaceutical companies, CPG conglomerates, and specialty health brands across 13+ product verticals, including oral health, energy and cognitive performance, jet lag, sleep and relaxation, sports electrolytes, pain management, smoking cessation, weight management, and more.
 
Our lead product, UltraPerio™, is a thermo-active oral health gum designed to deliver non-invasively comprehensive key therapeutic actives directly to unhealthy oral tissues — addressing one of the largest unmet needs in oral healthcare.
 
Founded and led by Dr. Daniel Sanders. UltraOral headquartered in Israel.

UltraOral Ltd

Org chart

Teams

Offices